Inclusion Criteria : 
   1.  Refractory or relapsed AML which will include : 
        1.  Refractory disease will be defined as at least  1 prior treatment with no remission . 
        2.  Relapsed disease will be defined as  5 % or more blasts in bone marrow seen after remission . 
        3.  Patients with AML arising from myelodysplastic syndromes ( including CMML ) or myeloproliferative neoplasms ( secondary AML , ts - AML ) are also eligible . 
   2.  Circulating blast count ≤  200 / μL within  10 days prior to first cycle of treatment .  Hydroxyurea should be used to keep the peripheral blast count ≤  200 / μL until the first day of protocol treatment , to the extent that this is possible
   3.  ECOG ≤  2 
   4.  Estimated creatinine clearance ≥  50 mL / min
   5.  AST and ALT ≤  3.0 x ULN
   6.  Bilirubin ≤  3.0 x ULN
Exclusion Criteria : 
   1.  Active CNS Leukemia . 
   2.  Known HIV infection or known hepatitis B or hepatitis C infection ( with a detectable viral load )  . 
   3.  Participant has received strong and / or moderate CYP 3A inducers within  7 days prior to the initiation of study treatment . 
   4.  Have received prior radiation to maximally tolerated levels to any critical normal organ . 
   5.  Clinically significant cardiac disease . 
   6.  Active , uncontrolled serious infection . 
   7.  Have other non - myeloid malignancy within  2 years of entry ( with exceptions )  . 
   8.  Psychiatric disorder that would preclude study participation
   9.  Previous solid organ transplant ( prior treatment with SCT is allowed but not if patient has GVHD or is still receiving immunosuppression / GVHD therapy )  .